Sai Parenterals Ltd

Sai Parenterals Limited has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited, an operating research and development center in Hyderabad, for ₹15 crore. The acquisition was funded from the unutilised net proceeds of the Company's initial public offering. Prathyak Laboratories, now renamed Sai Prathyak Laboratories Private Limited, becomes a direct subsidiary. This acquisition replaces the company's original plan to build a greenfield research center, providing an immediate operational platform with 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. The R&D center specializes in complex and oncology injectables, aligning with Sai Parenterals' strategy to build its regulated-market injectable franchise and support its Australian and New Zealand business. The company also has an option to acquire the remaining 40% stake through a Right of First Refusal.

Sai Parenterals Ltd. received a Monitoring Agency Report from India Ratings & Research Private Limited for the quarter ended June 30, 2026, concerning the utilization of IPO proceeds. The report highlights deviations amounting to INR 238.74 million (₹23.87 Crore) from the stated objects. Key deviations include INR 14.25 million (₹1.425 Crore) for capacity expansion not utilized on the same day, INR 1.28 million (₹0.128 Crore) paid as interest for borrowings, which was not a disclosed object, and INR 149.21 million (₹14.921 Crore) for general corporate purposes where funds were commingled, preventing independent verification of end utilization. Additionally, INR 4.28 million (₹0.428 Crore) from issue-related expenses was utilized after the reporting period, and INR 100.00 million (₹10 Crore) was paid to the BRLM without supporting invoices, though the company claims it was a refundable deposit. The company also delayed submitting required documents.

Sai Parenterals Ltd has announced that a board meeting will be held to declare its unaudited financial results for the quarter and half-year ended September 30, 2026. The trading window for dealing in the company's securities will be closed from October 1, 2026, until 48 hours after the declaration of these results, affecting all designated persons, their immediate relatives, and connected persons. The specific date of the board meeting will be intimated in due course.

Sai Parenterals Limited held a Board Meeting on September 30, 2026, approving key management changes. Ms. Shivali Aggarwal resigned as Company Secretary & Compliance Officer, effective September 30, 2026, due to personal reasons. The Board appointed Mr. Ashwani Singh Bisht as the new Company Secretary & Compliance Officer and Mr. Arvind Gannimitta as the Chief Operating Officer, both effective from September 30, 2026. Mr. Bisht is a qualified Company Secretary with over 12 years of experience, and Mr. Gannimitta brings over 26 years of experience in pharmaceutical operations.

Sai Parenterals Limited announced key management changes following a Board Meeting held on September 30, 2026. The company accepted the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer, effective the same day. Subsequently, Mr. Ashwani Singh Bisht was appointed as the new Company Secretary & Compliance Officer, and Mr. Arvind Gannimitta was appointed as the Chief Operating Officer, both effective September 30, 2026. Mr. Bisht brings over 12 years of experience in corporate secretarial functions, while Mr. Gannimitta has over 26 years of experience in pharmaceutical operations.

Sai Parenterals Ltd announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has successfully renewed a long-term Over-The-Counter (OTC) Medicines Supply Agreement with a major Australian pharmacy chain. The renewed agreement spans three years and is valued at AUD 30 million (approximately ₹204 Crores), representing an increase in both value and product portfolio compared to the previous contract. The agreement is effective from August 24, 2026, and includes provisions for revision or termination with a six-month notice. This renewal underscores the subsidiary's strong relationship with its international partner and its continued growth in the Australian market.

Sai Parenterals Limited's Australian subsidiary, Noumed Pharmaceuticals, has renewed its Over-The-Counter (OTC) Medicines Supply Agreement with a leading Australian pharmacy network. The 3-year deal is valued at AUD 30 million (approximately INR 204 crore) and includes an expanded product portfolio. Noumed will manage the full value chain, from manufacturing to distribution, under the pharmacy chain's own brand. This renewal enhances Sai Parenterals' earnings visibility and strengthens its position in regulated international markets. Combined with a previous renewal, the Australian OTC book now totals AUD 232 million (approx. INR 1,506 crore). The company plans to transition production in-house as its facilities commission, shifting from distribution margins to manufacturing margins.

Sai Parenterals Ltd has announced a book closure period from September 4th to September 10th, 2026, inclusive. This closure is for the purpose of the company's 25th Annual General Meeting (AGM), scheduled for September 10th, 2026, at 11:00 a.m. IST. The AGM will be conducted via Video Conference or Other Audio-Visual Means. The company has also fixed September 3rd, 2026, as the record date to identify shareholders eligible to vote electronically on the businesses to be transacted at the AGM.

Sai Parenterals Ltd has submitted its 25th Annual Report for the Financial Year 2025-26, in compliance with SEBI (LODR) Regulations, 2015. The report, dispatched to shareholders on August 19, 2026, details the company's evolution into an integrated pharmaceutical platform with strengths in branded generics and a scaling CDMO business. The company highlights its growing focus on injectables, R&D investments, and a manufacturing network with 1,160 million units of installed annual capacity across five facilities. International expansion through Noumed in Australia and New Zealand, including a renewed ₹1,300 Crore OTC medicines supply agreement, is also a key focus. The Annual General Meeting is scheduled for September 10, 2026, via Video Conference.

Sai Parenterals Ltd has announced its 25th Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled for September 10, 2026, at 11:00 AM via Video Conference. The company has complied with SEBI (LODR) Regulations, 2015, by submitting the AGM notice. The annual report, dispatched on August 19, 2026, is available on the company's website. The report highlights the company's evolution into an integrated pharmaceutical platform with a strong foundation in branded generics and a growing CDMO business. Investments in R&D and manufacturing capabilities, including a network of five facilities with significant capacity, are aimed at expanding into regulated markets and advancing its injectables portfolio. The company also notes its international presence through Noumed and a renewed OTC medicines supply agreement in Australia.